S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 6, 2007, Pages

  Martini, Sebastian ^a   Krämer, Stephanie ^a   Loof, Tanja ^a   Wang Rosenke, Yingrui ^a   Daig, Ute ^a   Budde, Klemens ^a   Neumayer, Hans H ^a   Peters, Harm ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute anti thy1 glomerulonephritis; Fibrosis; Lymphocytes; TGF

Indexed keywords

ANTIBODY; CANCER GROWTH FACTOR; COLLAGEN TYPE 3; FIBRONECTIN; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; SPHINGOSINE 1 PHOSPHATE MODULATOR; THY 1 ANTIBODY; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; DRUG DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPANEDIOL DERIVATIVE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL INFILTRATION; CONTROLLED STUDY; CYTOLYSIS; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MECHANISM; EXPERIMENTAL STUDY; EXTRACELLULAR MATRIX; HISTOLOGY; LYMPHOCYTE COUNT; MACROPHAGE; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECT; ENZYMOLOGY; GLOMERULUS; HEART RATE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LEUKOCYTE COUNT; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, THY-1; BLOOD PRESSURE; BODY WEIGHT; COLLAGEN TYPE III; EXTRACELLULAR MATRIX; FIBRONECTINS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEART RATE; IMMUNOHISTOCHEMISTRY; KIDNEY GLOMERULUS; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; NITRIC OXIDE SYNTHASE TYPE II; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPYLENE GLYCOLS; PROTEINURIA; RATS; RATS, WISTAR; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 34447640915     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00253.2006     Document Type: Article

References (27)

1. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 279: 15396-15401, 2004.
2. Appel GB, Waldman M. The IgA nephropathy treatment dilemma. Kidney Int 69: 1939-1944, 2006.
3. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 14: 569-575, 2002.
4. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219-229, 1984.
5. Floege J, Grone HJ. Glomerular cells in the progression of human and experimental nephropathies. Adv Nephrol Necker Hosp 27: 15-37, 1997.
6. Ikezumi Y, Kawachi H, Toyabe S, Uchiyama M, Shimizu F. An anti-CD5 monoclonal antibody ameliorates proteinuria and glomerular lesions in rat mesangioproliferative glomerulonephritis. Kidney Int 58: 100-114, 2000.
7. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355: 1124-1140, 2006.
8. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 318: 1657-1666, 1988.
9. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360, 2004.
10. Morales C, Gonzalez GE, Rodriguez M, Bertolasi CA, Gelpi RJ. Histopathologic time course of myocardial infarct in rabbit hearts. Cardiovasc Pathol 11: 339-345, 2002.
11. Narita I, Border WA, Ketteler M, Noble NA. Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72: 17-24, 1995.
12. Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol 29: 707-716, 2002.
13. Peters H, Border WA, Noble NA. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int 57: 992-1001, 2000.
14. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 54: 1570-1580, 1998.
15. Peters H, Border WA, Ruckert M, Kramer S, Neumayer HH, Noble NA. L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int 63: 1382-1392, 2003.
16. Peters H, Daig U, Martini S, Ruckert M, Schaper F, Liefeldt L, Kramer S, Neumayer HH. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int 64: 509-518, 2003.
17. Peters H, Martini S, Wang Y, Shimizu F, Kawachi H, Kramer S, Neumayer HH. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. Kidney Int 66: 1434-1443, 2004.
18. Peters H, Martini S, Woydt R, Ruckert M, Shimizu F, Kawachi H, Liefeldt L, Kramer S, Neumayer HH. Moderate alcohol intake has no impact on acute and chronic progressive anti-thy1 glomerulonephritis. Am J Physiol Renal Physiol 284: F1105-F1114, 2003.
19. Rabb H. The T cell as a bridge between innate and adaptive immune systems: implications for the kidney. Kidney Int 61: 1935-1946, 2002.
20. Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG. Enzyme-linked immunoassay (ELISA) for connective tissue components. Anal Biochem 104: 205-214, 1980.
21. Rodriguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59: 1626-1640, 2001.
22. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279: 13839-13848, 2004.
23. Suzuki S, Li XK, Shinomiya T, Enosawa S, Amemiya H, Amari M, Naoe S. The in vivo induction of lymphocyte apoptosis in MRL-lpr/lpr mice treated with FTY720. Clin Exp Immunol 107: 103-111, 1997.
24. Tawadrous MN, Mabuchi A, Zimmermann A, Wheatley AM. Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat. Transplantation 74: 602-610, 2002.
25. Tedesco-Silva H, Mourad G, Kahan BD, Boira JG, Weimar W, Mulgaonkar S, Nashan B, Madsen S, Charpentier B, Pellet P, Vanrenterghem Y. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79: 1553-1560, 2005.
26. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Br J Pharmacol 147: 164-174, 2006.
27. Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. Am J Physiol Renal Physiol 283: F1167-F1175, 2002.